Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea

(2014) Kwang Hyun Chung et al.   Gut and Liver

Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment ofHelicobacter pyloriInfection in Korea

(2013) Ji Yoon Moon et al.   Gut and Liver

Prevalence of Primary and Secondary Antimicrobial Resistance ofHelicobacter pyloriin Korea from 2003 through 2012

(2012) Jung Won Lee et al.   HELICOBACTER

Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough

(2011) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Treatment of Helicobacter pylori Infection 2011

(2011) Anthony O’Connor et al.   HELICOBACTER

Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance

(2011) Jun-Won Chung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Bismuth-Containing Quadruple Therapy as Second-Line Treatment forHelicobacter pyloriInfection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea

(2010) Byoung Hwan Lee et al.   HELICOBACTER

Treatment of Helicobacter pylori Infection 2010

(2010) Anthony O’Connor et al.   HELICOBACTER

Helicobacter pyloriInfection

(2010) Kenneth E.L. McColl   NEW ENGLAND JOURNAL OF MEDICINE

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

(2010) Yuqin Li et al.   WIENER KLINISCHE WOCHENSCHRIFT

Distribution ofgyrAmutations in fluoroquinolone-resistantHelicobacter pyloristrains

(2010) Li-Hui Wang   WORLD JOURNAL OF GASTROENTEROLOGY

Moxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate

(2009) Hyuk Yoon et al.   HELICOBACTER

Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication

(2009) Toshihiro Nishizawa et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial

(2009) Josip Bago et al.   WIENER KLINISCHE WOCHENSCHRIFT

S3-Guideline ”Helicobacter pylori and gastroduodenal ulcer disease” of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-Registration-no. 021 / 001

(2009) W. Fischbach et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE